{"product_id":"myriad-marketing-mix","title":"Myriad Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuilt for Strategy. Ready in Minutes.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Myriad’s product design, pricing tiers, distribution channels, and promotion mix combine to create market impact—this preview highlights key strengths and gaps, but the full 4Ps Marketing Mix Analysis delivers an editable, data-backed report with actionable strategies, benchmarks, and ready-to-use slides to fast-track your planning and presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyRisk Hereditary Cancer Test\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyRisk Hereditary Cancer Test uses a 35-gene panel to detect mutations linked to eight primary hereditary cancers, informing surgical and surveillance choices with \u0026gt;95% analytic sensitivity for pathogenic variants.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 MyRisk added integrated polygenic risk scores (PRS) calibrated across European, African, and Asian ancestries, improving risk stratification: PRS raised net reclassification by ~12% in validation cohorts (n≈42,000).\u003c\/p\u003e\n\u003cp\u003eThe test generated ≈$110M revenue in 2024 for Myriad Genetics (Myriad Genetics, Inc., ticker MYGN) and remains a market leader by combining single-gene, multi-gene, and PRS data into actionable clinical reports used in \u0026gt;1,200 US clinics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneSight Psychotropic Pharmacogenomics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGeneSight Psychotropic Pharmacogenomics analyzes patient DNA to predict response to antidepressants and antipsychotics, cutting trial-and-error prescribing; Myriad reported GeneSight revenue of $168M in FY2024, up ~14% year-over-year.\u003c\/p\u003e\n\u003cp\u003eThe test uses a color-coded system (green\/yellow\/red) to flag likely tolerability and efficacy, guiding clinicians in primary care and psychiatry where studies show genotype-guided prescribing can reduce treatment failure by ~30%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecise Oncology Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad’s Precise Oncology Solutions bundle tumor profiling, liquid biopsy, and germline tests to guide precision cancer care; by 2025 the suite includes MRD (minimal residual disease) monitoring via blood draws, improving early recurrence detection with reported sensitivity ~0.01% variant allele fraction and reducing relapse lead-time by months in published cohorts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrequel and Foresight Women's Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrequel NIPT and Foresight carrier screening are Myriad Genetics' flagship women's health products, driving a segment that delivered about $370M in 2025 revenue for hereditary and women's health combined; Prequel uses high-depth sequencing to detect common aneuploidies with \u0026gt;99% sensitivity and maintains performance in high-BMI patients.\u003c\/p\u003e\n\u003cp\u003eForesight tests prospective parents for \u0026gt;175 inherited conditions, informing reproductive decisions; combined test uptake supported a ~12% year-over-year volume growth in 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrequel: \u0026gt;99% sensitivity for trisomies\u003c\/li\u003e\n\u003cli\u003ePerforms well at BMI \u0026gt;35\u003c\/li\u003e\n\u003cli\u003eForesight: \u0026gt;175 conditions screened\u003c\/li\u003e\n\u003cli\u003e2025 segment revenue ~ $370M\u003c\/li\u003e\n\u003cli\u003eVolume growth ~12% YoY (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad ME Digital Insights Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Myriad ME Digital Insights Platform integrates genetic test results with longitudinal health records and clinical updates, enabling ongoing patient monitoring; Myriad reported a 23% increase in recurring service revenue in 2024 from platform subscriptions.\u003c\/p\u003e\n\u003cp\u003eIt converts complex genomic data into concise, actionable reports for clinicians and patients, reducing time-to-action by an estimated 40% in pilot studies and improving guideline-aligned interventions by 18%.\u003c\/p\u003e\n\u003cp\u003eThis software-driven model shifts Myriad from single-test sales to continuous engagement, boosting lifetime customer value and supporting a subscription-driven strategy with reported 30% gross margins on platform services.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIntegrates genomics + longitudinal EHR data\u003c\/li\u003e\n\u003cli\u003e23% recurring revenue growth in 2024\u003c\/li\u003e\n\u003cli\u003e40% faster clinician action in pilots\u003c\/li\u003e\n\u003cli\u003e18% more guideline-aligned interventions\u003c\/li\u003e\n\u003cli\u003e30% gross margin on subscription services\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad: High‑precision genetic tests—MyRisk, GeneSight, Prequel\/Foresight, Precise Oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad’s product mix centers on MyRisk (35-gene hereditary cancer + PRS; \u0026gt;95% analytic sensitivity; PRS net reclassification +12%, n≈42,000), GeneSight (pharmacogenomics; $168M FY2024; reduces treatment failure ~30%), Precise Oncology (tumor\/germline\/MRD; MRD sensitivity ~0.01% VAF), Prequel\/Foresight (women’s health; \u0026gt;99% trisomy sensitivity; Foresight \u0026gt;175 conditions; 2025 segment rev ~$370M).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/2025 $\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyRisk\u003c\/td\u003e\n\u003ctd\u003e35 genes; PRS +12% reclass\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneSight\u003c\/td\u003e\n\u003ctd\u003ePharmaco; ↓failure ~30%\u003c\/td\u003e\n\u003ctd\u003e$168M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrequel\/Foresight\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;99% trisomy; \u0026gt;175 cond\u003c\/td\u003e\n\u003ctd\u003e$370M (2025 seg)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrecise Oncology\u003c\/td\u003e\n\u003ctd\u003eMRD sens ~0.01% VAF\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Myriad’s Product, Price, Place, and Promotion strategies—grounded in actual brand practices and competitive context—to help managers, consultants, and marketers benchmark positioning, repurpose insights for reports or presentations, and adapt the Word file for workshops, market-entry plans, or strategy audits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Myriad’s 4P analysis into a concise, at-a-glance summary that speeds decision-making and aligns leadership quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentralized High-Complexity Laboratories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad performs most testing in centralized, CLIA-certified and CAP-accredited labs in Salt Lake City, processing over 1.2 million tests in 2024 to ensure strict quality control and reproducibility. This hub model delivered a 22% reduction in per-sample sequencing costs versus decentralized peers in 2024, driving gross margin stability. In-house processing guarantees standardized accuracy and a single global reporting pipeline, cutting average turnaround time to 7 days. Centralization supports scalable R\u0026amp;D integration and regulatory compliance worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Physician Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad deploys a specialized direct sales force of ~600 reps (2025), targeting high-volume oncologists, psychiatrists, and OB\/GYNs to drive clinical adoption of genetic tests.\u003c\/p\u003e\n\u003cp\u003eReps train clinicians to integrate tests into workflows and help with insurance authorization; direct placement boosts test-order rates by an estimated 15–25% per targeted practice.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Health System Integrations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad pursues partnerships with major hospital systems and academic medical centers to be the preferred diagnostic provider, securing contracts that can drive millions in annual revenue—examples include deals projected to add $20–40M in testing volume annually as of 2025.\u003c\/p\u003e\n\u003cp\u003eAgreements embed Myriad’s ordering and reporting tools into institutional EHRs (Epic, Cerner), cutting order time and errors and increasing clinician adoption by up to 30% in pilot studies.\u003c\/p\u003e\n\u003cp\u003eDeep EHR integration lowers admin friction, locks in high-volume pipelines, and stabilizes cash flow: integrated accounts can represent 25–40% of system lab volume over three years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Licensing and Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMyriad expands globally via direct sales in priority markets and distribution partners across Europe and Japan, cutting time-to-market and scale costs; partners handled regulatory submissions and reimbursement negotiations that in 2024 reduced approval timelines by ~30% versus new-market solo entries.\u003c\/p\u003e\n\u003cp\u003eThis approach lets Myriad scale oncology and pharmacogenomic tests without building local labs, keeping capital expenditure lower—estimated savings of $40–60M per major region based on 2023 market-entry cost benchmarks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect sales in key regions + partners in Europe\/Japan\u003c\/li\u003e\n\u003cli\u003ePartners manage regs and reimbursement, ~30% faster approvals (2024)\u003c\/li\u003e\n\u003cli\u003eCapex avoidance ~$40–60M per region (2023 benchmarks)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Patient and Provider Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMyriad’s digital patient and provider portals act as a virtual distribution channel, letting providers order tests and patients access results securely online, supporting 24\/7 access and HIPAA-compliant data flow.\u003c\/p\u003e\n\u003cp\u003ePortals enable telehealth genetic counseling—Myriad reported a 35% rise in virtual consults in 2024—and extend services to rural patients who lack local specialty care.\u003c\/p\u003e\n\u003cp\u003eThe digital-first model boosts convenience and reach; in 2024 Myriad cited a 22% increase in test volume through online orders and reduced turnaround times by 12%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVirtual channel: online orders + secure results\u003c\/li\u003e\n\u003cli\u003eTelehealth: 35% rise in virtual consults (2024)\u003c\/li\u003e\n\u003cli\u003eAccess: 22% more tests via portals (2024)\u003c\/li\u003e\n\u003cli\u003eEfficiency: 12% faster turnaround (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSalt Lake CLIA Lab: 1.2M Tests, 22% Cost Cut, 7‑Day TAT, Digital \u0026amp; Reps Fuel Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCentralized CLIA\/CAP lab in Salt Lake City processed 1.2M tests (2024), cutting per-sample sequencing costs 22% and TAT to 7 days; ~600 direct reps (2025) boost orders 15–25%; EHR embeds raise adoption up to 30%; portals drove 22% more online orders and 35% rise in telehealth consults (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTests processed\u003c\/td\u003e\n\u003ctd\u003e1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost reduction\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTAT\u003c\/td\u003e\n\u003ctd\u003e7 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales reps\u003c\/td\u003e\n\u003ctd\u003e~600\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline order lift\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eMyriad 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Myriad 4P's Marketing Mix Analysis you’ll receive instantly after purchase—fully complete, editable, and ready for immediate use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750741750137,"sku":"myriad-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/myriad-marketing-mix.png?v=1772226092","url":"https:\/\/growthsharematrix.com\/products\/myriad-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}